BR112023002078A2 - Preparação farmacêutica - Google Patents

Preparação farmacêutica

Info

Publication number
BR112023002078A2
BR112023002078A2 BR112023002078A BR112023002078A BR112023002078A2 BR 112023002078 A2 BR112023002078 A2 BR 112023002078A2 BR 112023002078 A BR112023002078 A BR 112023002078A BR 112023002078 A BR112023002078 A BR 112023002078A BR 112023002078 A2 BR112023002078 A2 BR 112023002078A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical preparation
methoxy
well
dihydroimidazo
quinolin
Prior art date
Application number
BR112023002078A
Other languages
English (en)
Inventor
Ambruosi Alessandra
Mannini Riccardo
RIEHL Markus
Becker Axel
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of BR112023002078A2 publication Critical patent/BR112023002078A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

PREPARAÇÃO FARMACÊUTICA. A presente invenção refere-se a uma preparação farmacêutica sólida de 8-(1,3-dimetil-1H-pirazol-4-il)-1-(Sa)-(3-fluoro-5-metóxi-piridin-4-il)-7-metóxi-3-metil-1,3-di-hidroimidazo[4,5-c]quinolin-2-ona, bem como um método para prepará-lo, bem como usos médicos dos mesmos.
BR112023002078A 2020-09-18 2021-09-15 Preparação farmacêutica BR112023002078A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20196904 2020-09-18
PCT/EP2021/075337 WO2022058351A1 (en) 2020-09-18 2021-09-15 Pharmaceutical preparation

Publications (1)

Publication Number Publication Date
BR112023002078A2 true BR112023002078A2 (pt) 2023-03-28

Family

ID=72561655

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023002078A BR112023002078A2 (pt) 2020-09-18 2021-09-15 Preparação farmacêutica

Country Status (13)

Country Link
US (1) US20230330027A1 (pt)
EP (1) EP4213803A1 (pt)
JP (1) JP2023542496A (pt)
KR (1) KR20230069147A (pt)
CN (1) CN116456969A (pt)
AR (1) AR123539A1 (pt)
AU (1) AU2021346097A1 (pt)
BR (1) BR112023002078A2 (pt)
CA (1) CA3190226A1 (pt)
IL (1) IL301412A (pt)
MX (1) MX2023002792A (pt)
TW (1) TW202227073A (pt)
WO (1) WO2022058351A1 (pt)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10531049B2 (en) 2015-03-31 2020-01-07 Nec Corporation Methods and systems for scheduling of sensing platform nodes
WO2016155884A1 (de) 2015-04-02 2016-10-06 Merck Patent Gmbh Imidazolonylchinoline und deren verwendung als atm kinase inhibitoren
CA3093499A1 (en) * 2018-03-14 2019-09-19 Merck Patent Gmbh Compounds and uses thereof to treat tumors in a subject
KR20210143263A (ko) * 2019-03-27 2021-11-26 메르크 파텐트 게엠베하 이미다졸로닐퀴놀린 화합물 및 그의 치료적 용도

Also Published As

Publication number Publication date
KR20230069147A (ko) 2023-05-18
AU2021346097A1 (en) 2023-03-09
AR123539A1 (es) 2022-12-14
CN116456969A (zh) 2023-07-18
IL301412A (en) 2023-05-01
US20230330027A1 (en) 2023-10-19
WO2022058351A1 (en) 2022-03-24
CA3190226A1 (en) 2022-03-24
JP2023542496A (ja) 2023-10-10
MX2023002792A (es) 2023-03-16
EP4213803A1 (en) 2023-07-26
TW202227073A (zh) 2022-07-16

Similar Documents

Publication Publication Date Title
CL2020001097A1 (es) Derivados de piridincarbonilo y usos terapéuticos de los mismos como inhibidores de trpc6.
EA201890852A1 (ru) Соли валбеназина и их полиморфы
EA201691151A1 (ru) Соединения для лечения пациентов с ros1-мутантными раковыми клетками
BR112015028501B8 (pt) Compostos derivados de bipirazol, seus sais, composição compreendendo o composto ou o sal, método de inibição in vitro de uma atividade de jak1, e processo de preparação de sal de ácido fosfórico
NI201100209A (es) DERIVADOS DE 1H - IMIDAZOL [ 4, 5 - c ] QUINOLINONA
MX2023000782A (es) 7-bencil-4-(2-metilbencilo)-2,4,6,7,8,9-hexahidroimidazo [1,2-a]pirido[3,4-e]pirimidin-5(1h)-ona, analogos y sales del mismo y su uso en terapia.
CO6382119A2 (es) Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades
BR112016004023A2 (pt) Composição, métodos para preparar uma composição e para tratar uma doença, e, composto
BR112019022512A2 (pt) Compostos de heteroarila bicíclica fundida 6-6 e seu uso como inibidores de lats
TR201802944T4 (tr) İlaç olarak azai̇ndazol veya di̇azai̇ndazol türünün türevleri̇
BR112015026023A2 (pt) derivados de 2- aminopirido[4,3-d]pirimidin-5-ona e seu uso como inibidores de wee-1
ECSP15006871A (es) 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos
EA201600337A1 (ru) 2,6-замещенные пуриновые производные и их применение в лечении пролиферативных заболеваний
CU20140037A7 (es) Derivados de estra- 1,3,5(10), 16- tetraen- 3- carboximida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos
DOP2015000005A (es) Derivados de estra 1,3,5(10), 16 tetraeno 3 sustituidos, métodos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos
BR112018007128A2 (pt) compostos para a inibição de câncer e epigênese
EA201991355A1 (ru) Производные имидазо[1,5-а]пиразина в качестве ингибиторов pi3kдельта
BR112021011325A2 (pt) Derivados de rapamicina
EA201001425A1 (ru) Азаиндольные соединения для лечения заболеваний центральной нервной системы
UY32829A (es) Derivados de 3-heteroaril-metil-imidazo-[1,2-b]-pirididazin - 6 -ilo
PH12018500796A1 (en) Cyclic ether derivatives of pyrazolo[1,5-a] pyrimidine-3-carboxamide
BR112017025395A2 (pt) formulações farmacêuticas para liberação prolongada de sebacoil éster de dinalbufina
BR112017020818A2 (pt) composto, uso de um composto, método, e, medicamento
BR112023002078A2 (pt) Preparação farmacêutica
MY182553A (en) Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions